Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management:
ASCVD, atherosclerotic cardiovascular disease
CTLA-4, cytotoxic T-lymphocyte associated protein 4
ICI, immune checkpoint inhibitor
IFN, interferon
IL, interleukin
PD-1, programmed cell death protein 1
PD-L1, programmed cell death ligand 1
TNF, tumor necrosis
atherosclerosis
cardio-oncology
cardiovascular disease
immune checkpoint inhibitor
inflammation
irAE, immune-related adverse event
Journal
JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
17
07
2022
accepted:
13
11
2022
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of the potential adverse effects of these drugs continues to broaden. Emerging evidence supports the association between ICI therapy with accelerated atherosclerosis and atherosclerotic cardiovascular (CV) events. We discuss the biological plausibility and the clinical evidence supporting an effect of inhibition of these immune checkpoints on atherosclerotic CV disease. Further, we provide a perspective on potential diagnostic and pharmacological strategies to reduce atherosclerotic risk in ICI-treated patients. Our understanding of the pathophysiology of ICI-related atherosclerosis is in its early stages. Further research is needed to identify the mechanisms linking ICI therapy to atherosclerosis, leverage the insight that ICI therapy provides into CV biology, and develop robust approaches to manage the expanding cohort of patients who may be at risk for atherosclerotic CV disease.
Identifiants
pubmed: 36636438
doi: 10.1016/j.jaccao.2022.11.011
pii: S2666-0873(22)00469-0
pmc: PMC9830225
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
598-615Subventions
Organisme : NIAID NIH HHS
ID : K24 AI157882
Pays : United States
Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Dr Neilan holds the Michael and Kathryn Park Endowed Chair in Cardiology and was also supported, in part, through a kind gift from A. Curtis Greer and Pamela Kohlberg and Christina and Paul Kazilionis, a Hassenfeld Scholar Award, and grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (R01HL130539, R01HL159187, R01HL137562, K24HL150238). Dr Zanni was supported, in part, through grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (R01HL146267 and R01HL137562) and from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (K24AI157882); and has served as the principal investigator on an investigator-initiated research grant from Gilead to her institution (Massachusetts General Hospital). Dr Neilan has served as a consultant for and received fees from Amgen, Genentech, Roche, BMS, Sanofi, CRC Oncology, and AbbVie outside of the current work; and received grant funding from AstraZeneca and Bristol Myers Squibb related to immune checkpoint inhibitors. Dr Suero-Abreu has reported that she has no relationships relevant to the contents of this paper to disclose.
Références
Atherosclerosis. 2019 Apr;283:69-78
pubmed: 30797988
Curr Opin Lipidol. 2018 Oct;29(5):381-388
pubmed: 30074493
Ann Oncol. 2018 Jan 1;29(1):284-286
pubmed: 29106493
J Natl Cancer Inst. 2021 Oct 1;113(10):1396-1404
pubmed: 33705549
Immunology. 2006 Nov;119(3):421-9
pubmed: 17067317
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
Sci Immunol. 2020 Jan 3;5(43):
pubmed: 31901074
Immunotherapy. 2015;7(6):655-67
pubmed: 26098609
JAMA Oncol. 2019 Jul 01;5(7):1008-1019
pubmed: 31021376
N Engl J Med. 2011 Dec 1;365(22):2078-87
pubmed: 22085316
Eur Heart J. 2021 Apr 21;42(16):1621-1631
pubmed: 33291147
J Clin Oncol. 2013 Feb 10;31(5):616-22
pubmed: 23295794
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
World J Cardiol. 2020 Nov 26;12(11):584-598
pubmed: 33312443
Cardiovasc Res. 2018 Aug 1;114(10):1360-1371
pubmed: 29726984
Cardiovasc Pathol. 2019 Nov - Dec;43:107148
pubmed: 31518915
Cancers (Basel). 2019 Dec 25;12(1):
pubmed: 31881699
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34145031
Cancer Res. 2017 Mar 1;77(5):1108-1118
pubmed: 28122327
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Eur Heart J. 2020 Aug 14;41(31):2938-2948
pubmed: 32728688
Eur J Cancer. 2021 Oct 15;158:99-110
pubmed: 34662835
Circ Res. 2018 Jun 8;122(12):1661-1674
pubmed: 29545365
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31512728
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32034065
J Am Coll Cardiol. 2018 Feb 6;71(5):527-542
pubmed: 29406859
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):549-563
pubmed: 33267666
Atherosclerosis. 2013 Sep;230(1):92-9
pubmed: 23958259
JAMA. 2004 Nov 10;292(18):2217-25
pubmed: 15536108
Nat Rev Immunol. 2013 Oct;13(10):709-21
pubmed: 23995626
Nat Nanotechnol. 2020 Feb;15(2):154-161
pubmed: 31988506
Coron Artery Dis. 2015 Nov;26(7):598-603
pubmed: 26166019
J Exp Med. 2014 Apr 7;211(4):715-25
pubmed: 24687957
Eur J Cancer. 2021 Feb;144:41-48
pubmed: 33326868
Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42
pubmed: 15345516
JACC CardioOncol. 2021 Mar;3(1):35-47
pubmed: 33842895
J Transl Med. 2018 Apr 11;16(1):94
pubmed: 29642948
JCI Insight. 2016 Oct 20;1(17):e88628
pubmed: 27777974
Cell Metab. 2019 Jul 2;30(1):143-156.e5
pubmed: 31031094
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Cells. 2020 Aug 29;9(9):
pubmed: 32872393
Circulation. 2006 Nov 7;114(19):2047-55
pubmed: 17060381
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
Nat Med. 2019 May;25(5):759-766
pubmed: 31036879
Int J Cardiol. 2021 Jan 1;322:177-182
pubmed: 32800916
Am J Cardiol. 2020 Jun 15;125(12):1920-1926
pubmed: 32312493
J Nucl Cardiol. 2005 May-Jun;12(3):294-301
pubmed: 15944534
Nature. 2016 Aug 4;536(7614):86-90
pubmed: 27437576
Eur Heart J. 2019 Dec 21;40(48):3937-3946
pubmed: 31121017
Nat Med. 2019 Oct;25(10):1576-1588
pubmed: 31591603
Cancer Discov. 2021 Mar;11(3):614-625
pubmed: 33257470
Cardiol Res. 2021 Oct;12(5):309-317
pubmed: 34691329
Front Immunol. 2020 Jul 07;11:1508
pubmed: 32733486
Circ Res. 2022 Feb 18;130(4):632-651
pubmed: 35175846
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855
pubmed: 30482962
Front Cardiovasc Med. 2021 Mar 30;8:652761
pubmed: 33860001
Int J Cardiol. 2013 Oct 3;168(3):1965-74
pubmed: 23351788
Cell. 2018 Nov 1;175(4):1059-1073.e21
pubmed: 30270039
Thromb Haemost. 2017 Jan 5;117(1):164-175
pubmed: 27786334
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
JAMA Netw Open. 2020 Mar 2;3(3):e200423
pubmed: 32150268
JAMA Oncol. 2019 Apr 01;5(4):529-536
pubmed: 30605213
EJNMMI Res. 2016 Dec;6(1):1
pubmed: 26728358
JACC CardioOncol. 2021 Dec 21;3(5):635-649
pubmed: 34988472
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Blood Adv. 2020 May 12;4(9):1917-1926
pubmed: 32380537
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Cardiovasc Res. 2018 Mar 1;114(3):368-377
pubmed: 29309533
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
JAMA Oncol. 2019 Nov 1;5(11):1635-1637
pubmed: 31436802
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32601081
Atherosclerosis. 2021 Oct;335:98-109
pubmed: 34593238
Int J Cardiovasc Imaging. 2014 Mar;30(3):571-82
pubmed: 24458953
Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628
pubmed: 31272931
Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1141-51
pubmed: 27055906
Circulation. 2020 Dec 15;142(24):2396-2398
pubmed: 32894978
Am J Med Sci. 2019 Apr;357(4):343-347
pubmed: 30638772
Circulation. 2018 May 22;137(21):2203-2214
pubmed: 29444987
PLoS One. 2015 Jun 02;10(6):e0128523
pubmed: 26035207
J Am Coll Cardiol. 2022 Feb 15;79(6):577-593
pubmed: 35144750
JACC Asia. 2022 Mar 29;2(2):157-167
pubmed: 36339124
J Clin Invest. 2007 Oct;117(10):2974-82
pubmed: 17853943
Nature. 2021 Apr;592(7855):524-533
pubmed: 33883728
J Cardiovasc Comput Tomogr. 2020 Mar - Apr;14(2):144-148
pubmed: 31451438
JACC CardioOncol. 2019 Dec 17;1(2):182-192
pubmed: 34396181
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Curr Oncol Rep. 2019 Apr 6;21(6):47
pubmed: 30955114
Circulation. 1996 Jan 1;93(1):34-41
pubmed: 8616937
Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2558-65
pubmed: 23990206
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
Circulation. 2017 Nov 21;136(21):2085-2087
pubmed: 29158217
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374804
AIDS. 2013 May 15;27(8):1263-72
pubmed: 23324657
J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):164-71
pubmed: 24828267
Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):20-33
pubmed: 31722535
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
JACC CardioOncol. 2021 Sep 21;3(3):360-380
pubmed: 34604797
Mol Imaging Biol. 2017 Feb;19(1):90-99
pubmed: 27430577
Cardiovasc Res. 2005 Apr 1;66(1):179-85
pubmed: 15769461
J Am Coll Cardiol. 2022 Jul 5;80(1):22-32
pubmed: 35772913
Eur Heart J. 2021 Dec 21;42(48):4964-4977
pubmed: 34529770
Circulation. 2020 Jun 16;141(24):2031-2034
pubmed: 32539614
Ann Transl Med. 2020 Dec;8(23):1597
pubmed: 33437796
J Clin Oncol. 2022 Oct 10;40(29):3430-3438
pubmed: 35772044
Nat Rev Immunol. 2018 Nov;18(11):669
pubmed: 30297717
Eur Heart J. 2017 Dec 21;38(48):3590-3599
pubmed: 29045618
Oncol Lett. 2020 Nov;20(5):176
pubmed: 32934743
Atherosclerosis. 2005 Nov;183(1):57-63
pubmed: 15941568
Thromb Res. 2020 Dec;196:444-453
pubmed: 33065409
Immunother Adv. 2021 Jun 16;1(1):ltab014
pubmed: 34541581
Biology (Basel). 2022 Mar 06;11(3):
pubmed: 35336782
J Neurosci Res. 2006 Aug 1;84(2):370-8
pubmed: 16676326
Circ Res. 2018 Jun 8;122(12):1675-1688
pubmed: 29545366
Nature. 2016 Mar 31;531(7596):651-5
pubmed: 26982734
Sci Rep. 2019 Jul 23;9(1):10608
pubmed: 31337788
Cardiovasc Res. 2013 Feb 1;97(2):349-59
pubmed: 23118130
Arterioscler Thromb Vasc Biol. 2020 Apr;40(4):865-873
pubmed: 32078338
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7
pubmed: 21393583
J Hematol Oncol. 2021 Oct 30;14(1):180
pubmed: 34717705
J Am Coll Cardiol. 2019 Sep 24;74(12):1543-1553
pubmed: 31537263
Nat Rev Drug Discov. 2022 Jul;21(7):482-483
pubmed: 35145263
JACC CardioOncol. 2020 Oct 06;2(4):599-610
pubmed: 34396271
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
N Engl J Med. 2021 Jan 28;384(4):382-383
pubmed: 33503349
J Mol Cell Cardiol. 2009 Feb;46(2):169-76
pubmed: 19056397
Cardiovasc Res. 2022 May 19;:
pubmed: 35587037
Circulation. 2001 Jul 10;104(2):197-202
pubmed: 11447086
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Can J Cardiol. 2020 Apr;36(4):476-481
pubmed: 32144037
Ann Oncol. 2017 Nov 1;28(11):2893-2895
pubmed: 28651328
Circulation. 2020 Dec 15;142(24):2299-2311
pubmed: 33003973
Circ Res. 2019 Jan 18;124(2):315-327
pubmed: 30653442
Circ Res. 2022 Feb 18;130(4):578-592
pubmed: 35175850
Mol Clin Oncol. 2019 Jan;10(1):137-143
pubmed: 30655989
Nature. 1998 Jul 9;394(6689):200-3
pubmed: 9671306
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S8-S20
pubmed: 29299404
Nature. 2020 Dec;588(7839):693-698
pubmed: 33177715
Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):295-305
pubmed: 29263187
Eur J Cancer. 2019 Oct;120:122-131
pubmed: 31518968
Ther Adv Med Oncol. 2020 Jul 24;12:1758835920913801
pubmed: 32782484
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830865
Front Oncol. 2021 Feb 22;11:579351
pubmed: 33692946
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
ESMO Open. 2020 Jan;5(1):
pubmed: 32516116
Nat Commun. 2021 Jun 18;12(1):3754
pubmed: 34145241
Int Immunol. 2007 Mar;19(3):337-43
pubmed: 17267414
PLoS One. 2014 Apr 01;9(4):e93280
pubmed: 24691202
Clin Cancer Res. 2021 Aug 15;27(16):4574-4586
pubmed: 34112709